FDAsafety guidance66% confidence
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Autoimmune Disorders
- Sub-indication
- Immunology
Related signal: FDA Accepts Supplement for LEQSELVI (Deuruxolitinib Phosphate) by Sun Pharma